Lineage Cell Therapeutics, Inc.
LCTX
$1.25
$0.086.84%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -40.91M | -16.21M | -18.61M | -20.11M | -24.19M |
| Total Depreciation and Amortization | 627.00K | 598.00K | 609.00K | 633.00K | 668.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 27.07M | 1.52M | 3.67M | 3.69M | 4.91M |
| Change in Net Operating Assets | -9.35M | -8.11M | -8.77M | -6.98M | -3.40M |
| Cash from Operations | -22.56M | -22.20M | -23.09M | -22.77M | -22.02M |
| Capital Expenditure | -588.00K | -624.00K | -565.00K | -291.00K | -318.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.00M | 257.00K | -1.74M | 5.09M | 3.35M |
| Cash from Investing | 8.41M | -367.00K | -2.31M | 4.80M | 3.03M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -55.00K | -55.00K | -54.00K | -53.00K | -52.00K |
| Issuance of Common Stock | 27.11M | 27.23M | 35.99M | 14.19M | 15.02M |
| Repurchase of Common Stock | -80.00K | -15.00K | -23.00K | -222.00K | -222.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -510.00K | -282.00K | -58.00K | 199.00K | 174.00K |
| Cash from Financing | 26.47M | 26.88M | 35.86M | 14.11M | 14.92M |
| Foreign Exchange rate Adjustments | 283.00K | -98.00K | -95.00K | 162.00K | -216.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.61M | 4.22M | 10.36M | -3.69M | -4.28M |